30 closest matches · ranked by relevance
COVID-19
Primary: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days. — 37; 52 Participants
Acute Coagulopathy
Primary: 28 Day In-hospital Mortality — 20; 11 participants — p=0.04
Trauma Injury
Primary: Number of Participants With Mortality From Any Cause — 201; 192 Participants
COVID
Primary: Coagulopathy Associated With COVID-19 — -313; -129.5 ng/mL FEU
COVID 19 Associated Coagulopathy
Primary: Mortality — 18; 13 Participants
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
Focus of Study · Coagulation Status of Cardiac Surgery Patient · Reducing Excess Blood Transfusion
Primary: Change in Thromboelastography-derived Functional Fibrinogen Level (FLEV) — -1.1 mg/dL
Hemorrhage · Coagulation Delay
Primary: Correlation of Fibrinogen in mg/dL Concentration With Clot Strength (CS hPa) and Fibrinogen Contribution to Clot (FCS hPa) of Point of the Care Quantra System. — 494…
Cirrhosis · Coagulopathy
Primary: Intra-operative Blood Loss — 2000; 3000 milliliters
Hypofibrinogenemia · Bleeding
Primary: Total Number of RBCs Used Over Admission — 5.8; 6.7 RBC Units
Bleeding · Blood Loss, Surgical · Cardiovascular Surgical Procedures
Primary: Chest Tube Output — 1022; 937 mL — p=0.84
Hemorrhagic Shock · Acute Blood Loss Anemia · Traumatic Brain Injury
Primary: Packed Red Blood Cells Equivalents Units Transfused (1 Whole Blood Unit Treated as 1 Packed Red Blood Cell Unit and 1 Fresh Frozen Plasma Unit) — 3.8; 5.7 units
Spinal Fusion · Cardiopulmonary Bypass
Primary: International Normalized Ratio (INR) on CoaguChek — 1.11; 4.6 ratio
Ischemic Stroke · Hyperglycemia
Primary: FVIIa — 69.7; 124.4 mU/ml
Congenital Heart Disease
Primary: Total Units of Intraoperative Allogenic Donor Transfusions (ADT) Administered During Procedure Through ICU Arrival. — 5; 4 ADT units
Acute Hypoxemic Respiratory Failure · Anticoagulant-induced Bleeding · Thromboembolism
Primary: Number of Participants With Major Bleeding Events — 1; 4 Participants
Acute ST Segment Elevation Myocardial Infarction
Primary: Platelet Inhibition Measured With Optical Aggregometry — 109; 253.8 AU*min
Acute Bleeding on Long-Term Anticoagulation Therapy · Hemorrhage · Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time)
Primary: Number of Participants Who Demonstrated Significant Reversal of INR Within 15 Minutes — 21; 33 Participants
Reversal of Anticoagulant Treatment
Primary: INR Response — 74; 31 Participants
Severe Sepsis · Coagulopathy
Primary: Number of Participants With 28-Day All-cause Mortality — 106; 119 Participants — p=0.318
Hemorrhagic Shock
Primary: Neutrophil Oxidative Burst Activity — 302; 302; 298; 268 Median Fluorescence Intensity — p=0.56
Hemorrhagic Shock
Primary: Biological Response as Characterized by Selected Cytokines, Specifically Tumor Necrosis Factor Alpha (TNFα), Interleukin One (IL-1β), and Interleukin Six (IL-6).
Liver Fibrosis
Primary: Median Liver Stiffness Value — 7.70; 6.90 kPa — p=0.043
Hemostasis
Primary: Clot Degradation at 24 Hours Post-operatively — 0.65; 0.88; 0.78; 0.46 microns per hour
Cardiopulmonary Bypass
Primary: Clot Time — 4.9; 3.3 min — p=<0.001
Anesthesia
Primary: r Time — 5.6; 4.2; 3.9; 6 minutes
Hemorrhage · Shock · Wounds and Injuries
Primary: Change in HLA-DR Expression on Monocytes 72 Hours After Drug or Placebo Administration in Patient Groups (0g TXA (Placebo); 2g TXA; 4g TXA)." — 0.503; 0.509; 0.532 fold…
COVID-19 · Venous Thromboses · Arterial Thrombosis
Primary: Total Number of Patients Who Were Alive and Without Venous/Thrombotic Events in ICU — 28; 31 Participants
Significant Bleeding Risk
Primary: Hemostatic Efficacy Rating by IEAB — 41; 50; 58; 47 Participants
Trauma
Primary: 24-hour Mortality — 43; 58 participants — p=0.12